Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
3期
已完成
NCT02283853
| 适应症 | Relapsing-Remitting Multiple Sclerosis |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Biogen |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 156 人 |
|---|
| 干预（药物） | dimethyl fumarate, Interferon β-1a |
|---|
| 开始日期 | 2014年8月28日 |
|---|
| 完成日期 | 2025年7月8日 |
|---|
| 结果公布日 | 2026年5月19日 |
|---|
摘要
The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and evolution of disability. The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306. The secondary objective of Part 2 is to describe the long-term MS outcomes of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306.
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans
At Week 96 · proportion of participants
| Part 1: BG00012 | 0.161 proportion of participants |
|---|
| Part 1: Interferon β-1a | 0.049 proportion of participants |
|---|
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
From Week 96 up to last follow-up visit (up to Week 340) · Participants
| Part 2: BG00012/ BG00012 | 49 Participants |
|---|
| Part 2: IFN β-1a/ BG00012 | 31 Participants |
|---|
| Part 2: BG00012/ BG00012 | 8 Participants |
|---|
| Part 2: IFN β-1a/ BG00012 | 2 Participants |
|---|
Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE
From Week 96 up to last follow-up visit (up to Week 340) · Participants
| Part 2: BG00012/ BG00012 | 2 Participants |
|---|
| Part 2: IFN β-1a/ BG00012 | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。